https://jielunzhiwai.com/https://jielunzhiwai.com/about/https://jielunzhiwai.com/articles/https://jielunzhiwai.com/articles/a-good-doctor-and-uncertainty/https://jielunzhiwai.com/articles/after-recitation/https://jielunzhiwai.com/articles/alzheimer-sabirnetug-target-binding-and-patient-benefit/https://jielunzhiwai.com/articles/astrazeneca-drug-relay/https://jielunzhiwai.com/articles/asundexian-stroke-benefit-and-bleeding-risk/https://jielunzhiwai.com/articles/avacopan-evidence-and-patient-choice/https://jielunzhiwai.com/articles/avacopan-settlement-update-2026-10-31/https://jielunzhiwai.com/articles/avacopan-trial-and-patients/https://jielunzhiwai.com/articles/avastin-breast-cancer-withdrawal/https://jielunzhiwai.com/articles/bioarctic-revenue-recognition-and-future-rights/https://jielunzhiwai.com/articles/bitopertin-clinical-success-investor-value/https://jielunzhiwai.com/articles/boehringer-sbp-oncology-option-deal/https://jielunzhiwai.com/articles/brain-organoids-consciousness/https://jielunzhiwai.com/articles/buddenbrooks-breath-classroom-and-feeling/https://jielunzhiwai.com/articles/buddenbrooks-hanno-awareness-and-action/https://jielunzhiwai.com/articles/buddenbrooks-reading-introduction/https://jielunzhiwai.com/articles/buddenbrooks-thomas-duty-and-self/https://jielunzhiwai.com/articles/buddenbrooks-women-culture-and-inheritance/https://jielunzhiwai.com/articles/cancer-vaccine-expectations/https://jielunzhiwai.com/articles/cancer-vaccine-four-doors/https://jielunzhiwai.com/articles/cancer-vaccine-three-studies/https://jielunzhiwai.com/articles/cancer-vaccine-two-gates/https://jielunzhiwai.com/articles/clinical-trials-reading-part-1/https://jielunzhiwai.com/articles/clinical-trials-reading-part-2/https://jielunzhiwai.com/articles/esmo-akeso-harmoni-gi1/https://jielunzhiwai.com/articles/esmo-hansoh-artemis-011/https://jielunzhiwai.com/articles/esmo-hengrui-her2-adc/https://jielunzhiwai.com/articles/esmo-hutchmed-saffron/https://jielunzhiwai.com/articles/esmo-kelun-three-trials/https://jielunzhiwai.com/articles/genmab-rina-s/https://jielunzhiwai.com/articles/glp1-rare-eye-risk-warning/https://jielunzhiwai.com/articles/hilbert-godel-limits-of-knowledge/https://jielunzhiwai.com/articles/how-many-people-support-a-family/https://jielunzhiwai.com/articles/huntington-amt130-patients-and-evidence/https://jielunzhiwai.com/articles/hyperemesis-gdf15/https://jielunzhiwai.com/articles/iga-kidney-evidence/https://jielunzhiwai.com/articles/individualized-gene-editing-fda-evidence-sharing/https://jielunzhiwai.com/articles/jnj-rybrevant-head-neck-accelerated-approval/https://jielunzhiwai.com/articles/lenacapavir-hiv-prevention-access/https://jielunzhiwai.com/articles/lilly-revenue-pricing-and-future-research/https://jielunzhiwai.com/articles/medical-progress-beyond-survival/https://jielunzhiwai.com/articles/mylotarg-return-to-approval/https://jielunzhiwai.com/articles/novavax-q3-2026-revenue-guidance/https://jielunzhiwai.com/articles/novo-nordisk-q3-2026-oral-wegovy-growth/https://jielunzhiwai.com/articles/olo-and-understanding/https://jielunzhiwai.com/articles/pfizer-q3-2026-growth-quality-and-cash/https://jielunzhiwai.com/articles/race-cars-community-cpr-and-patient-outcomes/https://jielunzhiwai.com/articles/recursion-ai-platform-clinical-evidence-and-value/https://jielunzhiwai.com/articles/references-and-becoming/https://jielunzhiwai.com/articles/relyvrio-waiting-for-evidence/https://jielunzhiwai.com/articles/report-card-a-and-learning/https://jielunzhiwai.com/articles/research-evidence-and-confusion/https://jielunzhiwai.com/articles/rhythm-lg-chem-royalty-fixed-payments/https://jielunzhiwai.com/articles/rrp-fewer-surgeries-dna-immunotherapy/https://jielunzhiwai.com/articles/same-dna-cell-fate/https://jielunzhiwai.com/articles/stem-cell-embryo-models-and-the-beginning-of-life/https://jielunzhiwai.com/articles/syd101-myopia-trial-success-and-fda-questions/https://jielunzhiwai.com/articles/vioxx-benefits-and-harms/https://jielunzhiwai.com/articles/when-medicine-changes-its-mind/https://jielunzhiwai.com/articles/when-technology-does-everything/https://jielunzhiwai.com/articles/when-thought-becomes-a-prison/https://jielunzhiwai.com/articles/who-bears-patient-losses/https://jielunzhiwai.com/articles/why-approved-drugs-are-withdrawn/https://jielunzhiwai.com/articles/zymeworks-nondilutive-financing-and-future-cash-flow/https://jielunzhiwai.com/courses/biopharma-investing/https://jielunzhiwai.com/courses/biopharma-investing/start/https://jielunzhiwai.com/en/https://jielunzhiwai.com/en/about/https://jielunzhiwai.com/en/articles/https://jielunzhiwai.com/en/articles/a-good-doctor-and-uncertainty/https://jielunzhiwai.com/en/articles/after-recitation/https://jielunzhiwai.com/en/articles/alzheimer-sabirnetug-target-binding-and-patient-benefit/https://jielunzhiwai.com/en/articles/astrazeneca-drug-relay/https://jielunzhiwai.com/en/articles/avacopan-evidence-and-patient-choice/https://jielunzhiwai.com/en/articles/avacopan-settlement-update-2026-10-31/https://jielunzhiwai.com/en/articles/avacopan-trial-and-patients/https://jielunzhiwai.com/en/articles/avastin-breast-cancer-withdrawal/https://jielunzhiwai.com/en/articles/bitopertin-clinical-success-investor-value/https://jielunzhiwai.com/en/articles/brain-organoids-consciousness/https://jielunzhiwai.com/en/articles/cancer-vaccine-expectations/https://jielunzhiwai.com/en/articles/cancer-vaccine-four-doors/https://jielunzhiwai.com/en/articles/cancer-vaccine-three-studies/https://jielunzhiwai.com/en/articles/clinical-trials-reading-part-1/https://jielunzhiwai.com/en/articles/clinical-trials-reading-part-2/https://jielunzhiwai.com/en/articles/esmo-akeso-harmoni-gi1/https://jielunzhiwai.com/en/articles/esmo-hansoh-artemis-011/https://jielunzhiwai.com/en/articles/esmo-hengrui-her2-adc/https://jielunzhiwai.com/en/articles/esmo-hutchmed-saffron/https://jielunzhiwai.com/en/articles/esmo-kelun-three-trials/https://jielunzhiwai.com/en/articles/fda-individualized-gene-editing-guide-rna/https://jielunzhiwai.com/en/articles/genmab-rina-s/https://jielunzhiwai.com/en/articles/hilbert-godel-limits-of-knowledge/https://jielunzhiwai.com/en/articles/huntington-amt130-patients-and-evidence/https://jielunzhiwai.com/en/articles/hyperemesis-gdf15/https://jielunzhiwai.com/en/articles/iga-kidney-evidence/https://jielunzhiwai.com/en/articles/jnj-rybrevant-head-neck-accelerated-approval/https://jielunzhiwai.com/en/articles/lenacapavir-hiv-prevention-access/https://jielunzhiwai.com/en/articles/lilly-revenue-pricing-and-future-research/https://jielunzhiwai.com/en/articles/medical-progress-beyond-survival/https://jielunzhiwai.com/en/articles/mylotarg-return-to-approval/https://jielunzhiwai.com/en/articles/novavax-q3-2026-revenue-guidance/https://jielunzhiwai.com/en/articles/novo-nordisk-q3-2026-oral-wegovy-growth/https://jielunzhiwai.com/en/articles/olo-and-understanding/https://jielunzhiwai.com/en/articles/race-cars-community-cpr-and-patient-outcomes/https://jielunzhiwai.com/en/articles/references-and-becoming/https://jielunzhiwai.com/en/articles/relyvrio-waiting-for-evidence/https://jielunzhiwai.com/en/articles/report-card-a-and-learning/https://jielunzhiwai.com/en/articles/research-evidence-and-confusion/https://jielunzhiwai.com/en/articles/rrp-fewer-surgeries-dna-immunotherapy/https://jielunzhiwai.com/en/articles/same-dna-cell-fate/https://jielunzhiwai.com/en/articles/stem-cell-embryo-models-and-the-beginning-of-life/https://jielunzhiwai.com/en/articles/vioxx-benefits-and-harms/https://jielunzhiwai.com/en/articles/when-medicine-changes-its-mind/https://jielunzhiwai.com/en/articles/when-technology-does-everything/https://jielunzhiwai.com/en/articles/when-thought-becomes-a-prison/https://jielunzhiwai.com/en/articles/who-bears-patient-losses/https://jielunzhiwai.com/en/articles/why-approved-drugs-are-withdrawn/https://jielunzhiwai.com/en/courses/biopharma-investing/https://jielunzhiwai.com/en/courses/biopharma-investing/start/https://jielunzhiwai.com/en/listen/https://jielunzhiwai.com/en/member/https://jielunzhiwai.com/en/privacy/https://jielunzhiwai.com/en/reading/https://jielunzhiwai.com/en/subscribe/https://jielunzhiwai.com/en/toolbox/https://jielunzhiwai.com/en/toolbox/10-k/https://jielunzhiwai.com/en/toolbox/accelerated-approval/https://jielunzhiwai.com/en/toolbox/acquisition-premium/https://jielunzhiwai.com/en/toolbox/adc/https://jielunzhiwai.com/en/toolbox/adverse-event/https://jielunzhiwai.com/en/toolbox/binding-offer/https://jielunzhiwai.com/en/toolbox/biomarker/https://jielunzhiwai.com/en/toolbox/blinding/https://jielunzhiwai.com/en/toolbox/cancer-vaccine/https://jielunzhiwai.com/en/toolbox/cash-flow/https://jielunzhiwai.com/en/toolbox/cash-runway/https://jielunzhiwai.com/en/toolbox/ci/https://jielunzhiwai.com/en/toolbox/closing/https://jielunzhiwai.com/en/toolbox/comparator/https://jielunzhiwai.com/en/toolbox/confirmatory-trial/https://jielunzhiwai.com/en/toolbox/contingent-consideration/https://jielunzhiwai.com/en/toolbox/contract-liability/https://jielunzhiwai.com/en/toolbox/cr/https://jielunzhiwai.com/en/toolbox/definitive-acquisition-agreement/https://jielunzhiwai.com/en/toolbox/dfs/https://jielunzhiwai.com/en/toolbox/dilution/https://jielunzhiwai.com/en/toolbox/dor/https://jielunzhiwai.com/en/toolbox/eps/https://jielunzhiwai.com/en/toolbox/hr/https://jielunzhiwai.com/en/toolbox/indication/https://jielunzhiwai.com/en/toolbox/itt/https://jielunzhiwai.com/en/toolbox/market-cap/https://jielunzhiwai.com/en/toolbox/median/https://jielunzhiwai.com/en/toolbox/non-binding-proposal/https://jielunzhiwai.com/en/toolbox/open-label/https://jielunzhiwai.com/en/toolbox/orr/https://jielunzhiwai.com/en/toolbox/os/https://jielunzhiwai.com/en/toolbox/person-years/https://jielunzhiwai.com/en/toolbox/pfs/https://jielunzhiwai.com/en/toolbox/phase-1/https://jielunzhiwai.com/en/toolbox/phase-2/https://jielunzhiwai.com/en/toolbox/phase-3/https://jielunzhiwai.com/en/toolbox/pr/https://jielunzhiwai.com/en/toolbox/primary-endpoint/https://jielunzhiwai.com/en/toolbox/randomization/https://jielunzhiwai.com/en/toolbox/real-world-data/https://jielunzhiwai.com/en/toolbox/relative-absolute-risk/https://jielunzhiwai.com/en/toolbox/revenue/https://jielunzhiwai.com/en/toolbox/single-arm-trial/https://jielunzhiwai.com/en/toolbox/surrogate-endpoint/https://jielunzhiwai.com/en/topics/https://jielunzhiwai.com/en/topics/after-approval/https://jielunzhiwai.com/en/topics/development/https://jielunzhiwai.com/en/topics/esmo-2026/https://jielunzhiwai.com/en/topics/evidence/https://jielunzhiwai.com/en/topics/ideas/https://jielunzhiwai.com/en/topics/oncology/https://jielunzhiwai.com/en/topics/regulation/https://jielunzhiwai.com/listen/https://jielunzhiwai.com/member/https://jielunzhiwai.com/privacy/https://jielunzhiwai.com/reading/https://jielunzhiwai.com/reading/unfinished/https://jielunzhiwai.com/reading/unfinished/buddenbrooks/https://jielunzhiwai.com/subscribe/https://jielunzhiwai.com/toolbox/https://jielunzhiwai.com/toolbox/10-k/https://jielunzhiwai.com/toolbox/accelerated-approval/https://jielunzhiwai.com/toolbox/acquisition-premium/https://jielunzhiwai.com/toolbox/adc/https://jielunzhiwai.com/toolbox/adverse-event/https://jielunzhiwai.com/toolbox/binding-offer/https://jielunzhiwai.com/toolbox/biomarker/https://jielunzhiwai.com/toolbox/blinding/https://jielunzhiwai.com/toolbox/cancer-vaccine/https://jielunzhiwai.com/toolbox/cash-flow/https://jielunzhiwai.com/toolbox/cash-runway/https://jielunzhiwai.com/toolbox/ci/https://jielunzhiwai.com/toolbox/closing/https://jielunzhiwai.com/toolbox/comparator/https://jielunzhiwai.com/toolbox/confirmatory-trial/https://jielunzhiwai.com/toolbox/contingent-consideration/https://jielunzhiwai.com/toolbox/contract-liability/https://jielunzhiwai.com/toolbox/cr/https://jielunzhiwai.com/toolbox/definitive-acquisition-agreement/https://jielunzhiwai.com/toolbox/dfs/https://jielunzhiwai.com/toolbox/dilution/https://jielunzhiwai.com/toolbox/dor/https://jielunzhiwai.com/toolbox/eps/https://jielunzhiwai.com/toolbox/hr/https://jielunzhiwai.com/toolbox/indication/https://jielunzhiwai.com/toolbox/investing/lesson-01/https://jielunzhiwai.com/toolbox/itt/https://jielunzhiwai.com/toolbox/market-cap/https://jielunzhiwai.com/toolbox/median/https://jielunzhiwai.com/toolbox/non-binding-proposal/https://jielunzhiwai.com/toolbox/open-label/https://jielunzhiwai.com/toolbox/orr/https://jielunzhiwai.com/toolbox/os/https://jielunzhiwai.com/toolbox/person-years/https://jielunzhiwai.com/toolbox/pfs/https://jielunzhiwai.com/toolbox/phase-1/https://jielunzhiwai.com/toolbox/phase-2/https://jielunzhiwai.com/toolbox/phase-3/https://jielunzhiwai.com/toolbox/pr/https://jielunzhiwai.com/toolbox/primary-endpoint/https://jielunzhiwai.com/toolbox/randomization/https://jielunzhiwai.com/toolbox/real-world-data/https://jielunzhiwai.com/toolbox/relative-absolute-risk/https://jielunzhiwai.com/toolbox/revenue/https://jielunzhiwai.com/toolbox/single-arm-trial/https://jielunzhiwai.com/toolbox/surrogate-endpoint/https://jielunzhiwai.com/topics/https://jielunzhiwai.com/topics/after-approval/https://jielunzhiwai.com/topics/development/https://jielunzhiwai.com/topics/esmo-2026/https://jielunzhiwai.com/topics/evidence/https://jielunzhiwai.com/topics/ideas/https://jielunzhiwai.com/topics/oncology/https://jielunzhiwai.com/topics/regulation/https://jielunzhiwai.com/zh-hant/about/https://jielunzhiwai.com/zh-hant/articles/a-good-doctor-and-uncertainty/https://jielunzhiwai.com/zh-hant/articles/after-recitation/https://jielunzhiwai.com/zh-hant/articles/alzheimer-sabirnetug-target-binding-and-patient-benefit/https://jielunzhiwai.com/zh-hant/articles/astrazeneca-drug-relay/https://jielunzhiwai.com/zh-hant/articles/asundexian-stroke-benefit-and-bleeding-risk/https://jielunzhiwai.com/zh-hant/articles/avacopan-evidence-and-patient-choice/https://jielunzhiwai.com/zh-hant/articles/avacopan-settlement-update-2026-10-31/https://jielunzhiwai.com/zh-hant/articles/avacopan-trial-and-patients/https://jielunzhiwai.com/zh-hant/articles/avastin-breast-cancer-withdrawal/https://jielunzhiwai.com/zh-hant/articles/bioarctic-revenue-recognition-and-future-rights/https://jielunzhiwai.com/zh-hant/articles/bitopertin-clinical-success-investor-value/https://jielunzhiwai.com/zh-hant/articles/boehringer-sbp-oncology-option-deal/https://jielunzhiwai.com/zh-hant/articles/brain-organoids-consciousness/https://jielunzhiwai.com/zh-hant/articles/buddenbrooks-breath-classroom-and-feeling/https://jielunzhiwai.com/zh-hant/articles/buddenbrooks-hanno-awareness-and-action/https://jielunzhiwai.com/zh-hant/articles/buddenbrooks-reading-introduction/https://jielunzhiwai.com/zh-hant/articles/buddenbrooks-thomas-duty-and-self/https://jielunzhiwai.com/zh-hant/articles/buddenbrooks-women-culture-and-inheritance/https://jielunzhiwai.com/zh-hant/articles/cancer-vaccine-expectations/https://jielunzhiwai.com/zh-hant/articles/cancer-vaccine-four-doors/https://jielunzhiwai.com/zh-hant/articles/cancer-vaccine-three-studies/https://jielunzhiwai.com/zh-hant/articles/cancer-vaccine-two-gates/https://jielunzhiwai.com/zh-hant/articles/clinical-trials-reading-part-1/https://jielunzhiwai.com/zh-hant/articles/clinical-trials-reading-part-2/https://jielunzhiwai.com/zh-hant/articles/esmo-akeso-harmoni-gi1/https://jielunzhiwai.com/zh-hant/articles/esmo-hansoh-artemis-011/https://jielunzhiwai.com/zh-hant/articles/esmo-hengrui-her2-adc/https://jielunzhiwai.com/zh-hant/articles/esmo-hutchmed-saffron/https://jielunzhiwai.com/zh-hant/articles/esmo-kelun-three-trials/https://jielunzhiwai.com/zh-hant/articles/genmab-rina-s/https://jielunzhiwai.com/zh-hant/articles/glp1-rare-eye-risk-warning/https://jielunzhiwai.com/zh-hant/articles/hilbert-godel-limits-of-knowledge/https://jielunzhiwai.com/zh-hant/articles/how-many-people-support-a-family/https://jielunzhiwai.com/zh-hant/articles/huntington-amt130-patients-and-evidence/https://jielunzhiwai.com/zh-hant/articles/hyperemesis-gdf15/https://jielunzhiwai.com/zh-hant/articles/iga-kidney-evidence/https://jielunzhiwai.com/zh-hant/articles/https://jielunzhiwai.com/zh-hant/articles/individualized-gene-editing-fda-evidence-sharing/https://jielunzhiwai.com/zh-hant/articles/jnj-rybrevant-head-neck-accelerated-approval/https://jielunzhiwai.com/zh-hant/articles/lenacapavir-hiv-prevention-access/https://jielunzhiwai.com/zh-hant/articles/lilly-revenue-pricing-and-future-research/https://jielunzhiwai.com/zh-hant/articles/medical-progress-beyond-survival/https://jielunzhiwai.com/zh-hant/articles/mylotarg-return-to-approval/https://jielunzhiwai.com/zh-hant/articles/novavax-q3-2026-revenue-guidance/https://jielunzhiwai.com/zh-hant/articles/novo-nordisk-q3-2026-oral-wegovy-growth/https://jielunzhiwai.com/zh-hant/articles/olo-and-understanding/https://jielunzhiwai.com/zh-hant/articles/pfizer-q3-2026-growth-quality-and-cash/https://jielunzhiwai.com/zh-hant/articles/race-cars-community-cpr-and-patient-outcomes/https://jielunzhiwai.com/zh-hant/articles/recursion-ai-platform-clinical-evidence-and-value/https://jielunzhiwai.com/zh-hant/articles/references-and-becoming/https://jielunzhiwai.com/zh-hant/articles/relyvrio-waiting-for-evidence/https://jielunzhiwai.com/zh-hant/articles/report-card-a-and-learning/https://jielunzhiwai.com/zh-hant/articles/research-evidence-and-confusion/https://jielunzhiwai.com/zh-hant/articles/rhythm-lg-chem-royalty-fixed-payments/https://jielunzhiwai.com/zh-hant/articles/rrp-fewer-surgeries-dna-immunotherapy/https://jielunzhiwai.com/zh-hant/articles/same-dna-cell-fate/https://jielunzhiwai.com/zh-hant/articles/stem-cell-embryo-models-and-the-beginning-of-life/https://jielunzhiwai.com/zh-hant/articles/syd101-myopia-trial-success-and-fda-questions/https://jielunzhiwai.com/zh-hant/articles/vioxx-benefits-and-harms/https://jielunzhiwai.com/zh-hant/articles/when-medicine-changes-its-mind/https://jielunzhiwai.com/zh-hant/articles/when-technology-does-everything/https://jielunzhiwai.com/zh-hant/articles/when-thought-becomes-a-prison/https://jielunzhiwai.com/zh-hant/articles/who-bears-patient-losses/https://jielunzhiwai.com/zh-hant/articles/why-approved-drugs-are-withdrawn/https://jielunzhiwai.com/zh-hant/articles/zymeworks-nondilutive-financing-and-future-cash-flow/https://jielunzhiwai.com/zh-hant/courses/biopharma-investing/https://jielunzhiwai.com/zh-hant/courses/biopharma-investing/start/https://jielunzhiwai.com/zh-hant/https://jielunzhiwai.com/zh-hant/listen/https://jielunzhiwai.com/zh-hant/member/https://jielunzhiwai.com/zh-hant/privacy/https://jielunzhiwai.com/zh-hant/reading/https://jielunzhiwai.com/zh-hant/reading/unfinished/buddenbrooks/https://jielunzhiwai.com/zh-hant/reading/unfinished/https://jielunzhiwai.com/zh-hant/subscribe/https://jielunzhiwai.com/zh-hant/toolbox/10-k/https://jielunzhiwai.com/zh-hant/toolbox/accelerated-approval/https://jielunzhiwai.com/zh-hant/toolbox/acquisition-premium/https://jielunzhiwai.com/zh-hant/toolbox/adc/https://jielunzhiwai.com/zh-hant/toolbox/adverse-event/https://jielunzhiwai.com/zh-hant/toolbox/binding-offer/https://jielunzhiwai.com/zh-hant/toolbox/biomarker/https://jielunzhiwai.com/zh-hant/toolbox/blinding/https://jielunzhiwai.com/zh-hant/toolbox/cancer-vaccine/https://jielunzhiwai.com/zh-hant/toolbox/cash-flow/https://jielunzhiwai.com/zh-hant/toolbox/cash-runway/https://jielunzhiwai.com/zh-hant/toolbox/ci/https://jielunzhiwai.com/zh-hant/toolbox/closing/https://jielunzhiwai.com/zh-hant/toolbox/comparator/https://jielunzhiwai.com/zh-hant/toolbox/confirmatory-trial/https://jielunzhiwai.com/zh-hant/toolbox/contingent-consideration/https://jielunzhiwai.com/zh-hant/toolbox/contract-liability/https://jielunzhiwai.com/zh-hant/toolbox/cr/https://jielunzhiwai.com/zh-hant/toolbox/definitive-acquisition-agreement/https://jielunzhiwai.com/zh-hant/toolbox/dfs/https://jielunzhiwai.com/zh-hant/toolbox/dilution/https://jielunzhiwai.com/zh-hant/toolbox/dor/https://jielunzhiwai.com/zh-hant/toolbox/eps/https://jielunzhiwai.com/zh-hant/toolbox/hr/https://jielunzhiwai.com/zh-hant/toolbox/https://jielunzhiwai.com/zh-hant/toolbox/indication/https://jielunzhiwai.com/zh-hant/toolbox/investing/lesson-01/https://jielunzhiwai.com/zh-hant/toolbox/itt/https://jielunzhiwai.com/zh-hant/toolbox/market-cap/https://jielunzhiwai.com/zh-hant/toolbox/median/https://jielunzhiwai.com/zh-hant/toolbox/non-binding-proposal/https://jielunzhiwai.com/zh-hant/toolbox/open-label/https://jielunzhiwai.com/zh-hant/toolbox/orr/https://jielunzhiwai.com/zh-hant/toolbox/os/https://jielunzhiwai.com/zh-hant/toolbox/person-years/https://jielunzhiwai.com/zh-hant/toolbox/pfs/https://jielunzhiwai.com/zh-hant/toolbox/phase-1/https://jielunzhiwai.com/zh-hant/toolbox/phase-2/https://jielunzhiwai.com/zh-hant/toolbox/phase-3/https://jielunzhiwai.com/zh-hant/toolbox/pr/https://jielunzhiwai.com/zh-hant/toolbox/primary-endpoint/https://jielunzhiwai.com/zh-hant/toolbox/randomization/https://jielunzhiwai.com/zh-hant/toolbox/real-world-data/https://jielunzhiwai.com/zh-hant/toolbox/relative-absolute-risk/https://jielunzhiwai.com/zh-hant/toolbox/revenue/https://jielunzhiwai.com/zh-hant/toolbox/single-arm-trial/https://jielunzhiwai.com/zh-hant/toolbox/surrogate-endpoint/https://jielunzhiwai.com/zh-hant/topics/after-approval/https://jielunzhiwai.com/zh-hant/topics/development/https://jielunzhiwai.com/zh-hant/topics/esmo-2026/https://jielunzhiwai.com/zh-hant/topics/evidence/https://jielunzhiwai.com/zh-hant/topics/ideas/https://jielunzhiwai.com/zh-hant/topics/https://jielunzhiwai.com/zh-hant/topics/oncology/https://jielunzhiwai.com/zh-hant/topics/regulation/